Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Penile Neoplasms 1Condylomata Acuminata 1Anus Neoplasms 1

Interventions

Cyclophosphamide 7pembrolizumab 6fludarabine 6aldesleukin 4fludarabine phosphate 2entinostat 2Trastuzumab 2Radiotherapy 2Psychiatric Rehabilitation 2Nivolumab 2Interleukin-2 2Interleukin-12 Subunit p35 2Early Intervention, Educational 2Adoptive Transfer 2trastuzumab deruxtecan 1tislelizumab 1tipifarnib 1spartalizumab 1rocakinogene sifuplasmid 1oncogene protein E7, Human papillomavirus type 16 1enzalutamide 1durvalumab 1cemiplimab 1bintrafusp alfa protein, human 1atezolizumab 1alovudine 1abiraterone 1Vorinostat 1Vaccines, Synthetic 1VGX-3100 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anus Neoplasms × Vaccines, Synthetic × Genitourinary × Clear all
NCT06465914 2024-12-12

A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males

Shanghai Bovax Biotechnology Co., Ltd.

Phase 3 Active not recruiting
9,000 enrolled
GastrointestinalGenitourinary

Anus Neoplasms, Condylomata Acuminata, Penile Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡